Supplementary Figure 10 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Biagio Ricciuti; Arielle Elkrief; Joao V. Alessi; Xinan Wang; Yvonne Li; Hersh Gupta; Daniel M. Muldoon; Arrien A. Bertram; Federica Pecci; Giuseppe Lamberti; Alessandro Di Federico; Adriana Barrichello; Victor R. Vaz; Malini Gandhi; Elinton Lee; Geoffrey I. Shapiro; Hyesun Park; Mizuki Nishino; James Lindsay; Kristen D. Felt; Bijaya Sharma; Andrew D. Cherniack; Scott J. Rodig; Daniel R. Gomez; Narek Shaverdian; Mehrdad Rakaee; Chaitanya Bandlamudi; Marc Ladanyi; Pasi A. Jänne; Adam J. Schoenfeld; Lynette M. Sholl; Mark M. Awad; Michael L. Cheng

doi:10.1158/1078-0432.27031231.v1

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Supplementary Figure 10. (A) Progression-free and (B) overall survival among all patients with stage III NSCLC according to ATM mutation status. (C) Progression-free and (D) overall survival among patients with stage III NSCLC who received concurrent chemoradiotherapy followed by durvalumab maintenance according to ATM mutation status.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ricciuti et al. (2024) studied this question.

synapsesocial.com/papers/68e587eeb6db643587523ec8 https://doi.org/10.1158/1078-0432.27031231.v1

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure 10 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Supplementary Figure 10 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading